(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.



Fig. 3. FHOS co-localizes, aggregates and caps with CD21 in response to cell surface EBV binding. (a) FHOS co-localizes with aggregated CD21. Transfected 293T cells expressing EGFP-FHOS (green) and CD21 were co-stained with an isotype control mAb (UPC10; panel 2) or with anti-CD21 (mAb HB-5; panels 5 and 8) followed by goat F(ab')2 anti-mouse IgG-R-PE (red). Cells challenged with concentrated EBV are shown in panels 4-9. Merged imaged (panel 4 with 5 and panel 7 with 8) are shown in panels 6 and 9 respectively. (b) The C terminus of FHOS is required for efficient aggregation and co-localization. Transfected HeLa cells expressing either FHOS (EGFP-FHOS, green; panels 1-9) or FHOS{Delta}CT (EGFP-FHOS{Delta}CT, green; panels 10-15) and CD21 (red; stained as in a) were incubated with EBV (panels 4-9 and 13-15) or without EBV (panels 1-3 and 10-12). Merged images of FHOS with CD21 are shown in panels 3 (panel 1+2), 6 (panel 4+5) and 9 (panel 7+8). Merged images for FHOS{Delta}CT with CD21 are shown in panels 12 (panel 10+11) and 15 (panel 13+14). All cells were fixed, stained and imaged as stated in Fig. 2.